Quantum Cyber N.V. QUCY
tests for the early detection of cancer. In March 2025, we acquired a license from Liquid Bioscience, Inc. to access a portfolio of novel
mRNA biomarkers and AI developed proprietary algorithm, for the non-invasive detection of pancreatic cancer with a blood test. We have
an exclusive license to develop such a test using these biomarkers and algorithm with the unilateral option to acquire them. We are also
developing a product candidate called PancAlert, a stool-based screening test aimed at detecting pancreatic cancer. We have received non-refundable
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $537.1K | $894.0K | $895.5K | $529.9K | $577.3K | $493.6K | $281.4K | — |
| Cost of revenue | $147.3K | $319.1K | — | — | — | — | — | — |
| Gross profit | $389.8K | $574.9K | — | — | — | — | — | — |
| R&D | $4.9M | $5.7M | — | — | — | — | — | — |
| SG&A | $5.1M | $6.7M | — | — | — | — | — | — |
| Total operating expenses | $16.5M | $19.3M | — | — | — | — | — | — |
| Operating income | -$16.1M | -$18.8M | -$26.6M | -$26.4M | -$9.7M | -$673.7K | -$921.9K | — |
| Interest expense | $373.5K | $945.5K | — | — | — | — | — | — |
| Pre-tax income | -$16.2M | -$21.6M | — | — | — | — | — | — |
| Net income | -$16.2M | -$21.6M | -$26.3M | -$26.4M | -$11.7M | -$586.9K | -$957.1K | — |
| EPS, basic | -2.70 | -21.91 | — | — | — | — | — | — |
| EPS, diluted | -2.70 | -21.91 | — | — | — | — | — | — |
| Shares, diluted (wtd. avg.) | 6.0M | 985,717 | — | — | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $889.1K | $6.2M | $7.1M | — | — | — | — | — |
| Inventory | $216.9K | $372.9K | — | — | — | — | — | — |
| Total current assets | $1.8M | $8.0M | — | — | — | — | — | — |
| Property, plant and equipment | $1.1M | $1.4M | — | — | — | — | — | — |
| Other intangibles | $1.1M | $3.0M | — | — | — | — | — | — |
| Total assets | $5.3M | $13.5M | $15.4M | $20.2M | $10.0M | $673.3K | — | — |
| Accounts payable | $411.1K | $1.3M | — | — | — | — | — | — |
| Short-term debt | $956.9K | $1.0M | — | — | — | — | — | — |
| Total current liabilities | $3.7M | $6.2M | — | — | — | — | — | — |
| Total liabilities | $4.7M | $7.5M | — | — | — | — | — | — |
| Retained earnings | -$104.9M | -$88.7M | — | — | — | — | — | — |
| Total equity | $641.6K | $6.0M | $3.4M | $14.1M | $6.4M | -$2.7M | -$2.0M | -$1.1M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.0M | -$17.3M | — | — | — | — | — | — |
| Depreciation and amortisation | $615.7K | $696.6K | — | — | — | — | — | — |
| Stock-based compensation | $1.5M | -$63.1K | — | — | — | — | — | — |
| Capital expenditure | $1.2K | $104.9K | — | — | — | — | — | — |
| Investing cash flow | -$1.0M | -$198.8K | — | — | — | — | — | — |
| Financing cash flow | $6.8M | $16.8M | — | — | — | — | — | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001213900-26-037676.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | $281.4K | $493.6K | $577.3K | $529.9K | $895.5K | $894.0K | $537.1K |
| Gross profit | — | — | — | — | — | — | $574.9K | $389.8K |
| Net income | — | -$957.1K | -$586.9K | -$11.7M | -$26.4M | -$26.3M | -$21.6M | -$16.2M |
Recent filings and events
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Acquisition or disposal completed A purchase or sale of a significant business or asset has closed. Item 2.01
- Regulation FD disclosure Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Other event Item 8.01
- Auditor changed The company changed auditors. Sometimes routine; historically one of the more reliable warnings that something is wrong. Item 4.01
- Material agreement signed Item 1.01
- Regulation FD disclosure Item 7.01
- Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |